You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLisdexamfetamine
Accession NumberDB01255
TypeSmall Molecule
GroupsApproved, Investigational
Description

Lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin.

Structure
Thumb
Synonyms
Lisdexamfetamine
lisdexamfetamine dimesylate
NRP104
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vyvansecapsule60 mgoralShire Pharma Canada Ulc2010-04-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vyvansecapsule20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule30 mg/1oralShire LLC2007-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule50 mgoralShire Pharma Canada Ulc2009-08-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vyvansecapsule20 mg/1oralShire LLC2007-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule30 mgoralShire Pharma Canada Ulc2009-08-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vyvansecapsule10 mg/1oralShire LLC2014-08-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule70 mg/1oralAvera Mc Kennan Hospital2015-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule40 mg/1oralPhysicians Total Care, Inc.2009-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule70 mg/1oralShire LLC2007-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule30 mg/1oralPhysicians Total Care, Inc.2008-07-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule60 mg/1oralShire LLC2007-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule50 mg/1oralPhysicians Total Care, Inc.2008-07-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule50 mg/1oralShire LLC2007-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule40 mgoralShire Pharma Canada Ulc2010-04-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vyvansecapsule10 mgoralShire Pharma Canada Ulc2015-06-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vyvansecapsule70 mg/1oralPhysicians Total Care, Inc.2010-03-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule40 mg/1oralShire LLC2007-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vyvansecapsule20 mgoralShire Pharma Canada Ulc2010-04-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
UNIIH645GUL8KJ
CAS number608137-32-2
WeightAverage: 263.3785
Monoisotopic: 263.199762437
Chemical FormulaC15H25N3O
InChI KeyInChIKey=VOBHXZCDAVEXEY-JSGCOSHPSA-N
InChI
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
IUPAC Name
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
SMILES
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • Amphetamine or derivatives
  • Phenylpropane
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric populations aged 6 to 12 years.
PharmacodynamicsLisdexamfetamine is a pro-drug of dextroamphetamine. It works primarily by inducing the release of the neurotransmitters dopamine and norepinephrine from their storage areas in nerve terminals. Both of these transmitters contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation.
Mechanism of actionLisdexamfetamine is a pro-drug of dextroamphetamine. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Norepinephrine and dopamine contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation. However, the exact therapeutic action in ADHD is not known.
AbsorptionAfter oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Lisdexamfetamine is converted to dextroamphetamine and L-lysine, which is believed to occur by first-pass intestinal and/or hepatic metabolism. Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.

Route of eliminationNot Available
Half lifeThe plasma elimination half-life of lisdexamfetamine typically averaged less than one hour.
ClearanceNot Available
ToxicityManifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9858
Blood Brain Barrier+0.9444
Caco-2 permeable+0.664
P-glycoprotein substrateSubstrate0.6919
P-glycoprotein inhibitor INon-inhibitor0.9264
P-glycoprotein inhibitor IINon-inhibitor0.9802
Renal organic cation transporterNon-inhibitor0.8398
CYP450 2C9 substrateNon-substrate0.8303
CYP450 2D6 substrateNon-substrate0.621
CYP450 3A4 substrateNon-substrate0.7228
CYP450 1A2 substrateNon-inhibitor0.7025
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.7568
CYP450 3A4 inhibitorNon-inhibitor0.5499
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8494
Ames testNon AMES toxic0.7156
CarcinogenicityNon-carcinogens0.854
BiodegradationNot ready biodegradable0.8575
Rat acute toxicity2.0058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9688
hERG inhibition (predictor II)Non-inhibitor0.9004
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg/1
Capsuleoral10 mg
Capsuleoral20 mg/1
Capsuleoral20 mg
Capsuleoral30 mg
Capsuleoral30 mg/1
Capsuleoral40 mg
Capsuleoral40 mg/1
Capsuleoral50 mg/1
Capsuleoral50 mg
Capsuleoral60 mg/1
Capsuleoral60 mg
Capsuleoral70 mg/1
Prices
Unit descriptionCostUnit
Vyvanse 30 mg capsule6.24USD capsule
Vyvanse 50 mg capsule6.02USD capsule
Vyvanse 70 mg capsule5.85USD capsule
Vyvanse 40 mg capsule5.8USD capsule
Vyvanse 20 mg capsule5.26USD capsule
Vyvanse 60 mg capsule5.02USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States71054862003-06-292023-06-29
United States76556302003-02-242023-02-24
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility792 mg/mL (dimesylate salt)Not Available
logP1.06Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0877 mg/mLALOGPS
logP1.01ALOGPS
logP1.14ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.89ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area81.14 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.31 m3·mol-1ChemAxon
Polarizability31.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher, “Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof.” U.S. Patent US20120157706, issued June 21, 2012.

US20120157706
General References
  1. Jasinski DR, Krishnan S: Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2008 Jul 17. Pubmed
  2. Madaan V: Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc). 2008 May;44(5):319-24. Pubmed
  3. Krishnan S, Moncrief S: An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):180-4. Epub 2006 Oct 11. Pubmed
External Links
ATC CodesN06BA12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Lisdexamfetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of Lisdexamfetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Lisdexamfetamine.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmisulprideAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Lisdexamfetamine.
Ammonium chlorideThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Ammonium chloride.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Lisdexamfetamine.
AripiprazoleAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Lisdexamfetamine.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Lisdexamfetamine.
BenzquinamideBenzquinamide may decrease the stimulatory activities of Lisdexamfetamine.
BrompheniramineLisdexamfetamine may decrease the sedative activities of Brompheniramine.
Calcium AcetateCalcium Acetate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
CarphenazineCarphenazine may decrease the stimulatory activities of Lisdexamfetamine.
ChlormezanoneChlormezanone may decrease the stimulatory activities of Lisdexamfetamine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Lisdexamfetamine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Lisdexamfetamine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Lisdexamfetamine.
ClozapineClozapine may decrease the stimulatory activities of Lisdexamfetamine.
DiclofenamideDiclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Lisdexamfetamine.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Lisdexamfetamine.
DoxofyllineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Lisdexamfetamine.
DroperidolDroperidol may decrease the stimulatory activities of Lisdexamfetamine.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Lisdexamfetamine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Lisdexamfetamine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
FencamfamineFencamfamine may decrease the stimulatory activities of Lisdexamfetamine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Lisdexamfetamine.
FlupentixolFlupentixol may decrease the stimulatory activities of Lisdexamfetamine.
FluphenazineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.
FluspirileneFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Lisdexamfetamine.
HaloperidolHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.
HexamethylenetetramineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Hexamethylenetetramine.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Lisdexamfetamine.
Ioflupane I 123Lisdexamfetamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Lisdexamfetamine.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisdexamfetamine.
LinezolidLinezolid may increase the hypertensive activities of Lisdexamfetamine.
LithiumLithium may decrease the stimulatory activities of Lisdexamfetamine.
LoxapineLoxapine may decrease the stimulatory activities of Lisdexamfetamine.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Lisdexamfetamine.
MesoridazineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Lisdexamfetamine.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Lisdexamfetamine.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Lisdexamfetamine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Lisdexamfetamine.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Lisdexamfetamine.
MolindoneMolindone may decrease the stimulatory activities of Lisdexamfetamine.
MorphineLisdexamfetamine may increase the analgesic activities of Morphine.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Lisdexamfetamine.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Lisdexamfetamine.
OlanzapineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.
OndansetronOndansetron may decrease the stimulatory activities of Lisdexamfetamine.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Lisdexamfetamine.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisdexamfetamine.
PaliperidonePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.
PerphenazinePerphenazine may decrease the stimulatory activities of Lisdexamfetamine.
PhenelzinePhenelzine may increase the hypertensive activities of Lisdexamfetamine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Lisdexamfetamine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Lisdexamfetamine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Lisdexamfetamine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Lisdexamfetamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Lisdexamfetamine.
PimozidePimozide may decrease the stimulatory activities of Lisdexamfetamine.
PiperacetazinePiperacetazine may decrease the stimulatory activities of Lisdexamfetamine.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
PromazinePromazine may decrease the stimulatory activities of Lisdexamfetamine.
QuetiapineQuetiapine may decrease the stimulatory activities of Lisdexamfetamine.
RemoxiprideRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.
ReserpineReserpine may decrease the stimulatory activities of Lisdexamfetamine.
RisperidoneRisperidone may decrease the stimulatory activities of Lisdexamfetamine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Lisdexamfetamine.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Lisdexamfetamine.
SertindoleSertindole may decrease the stimulatory activities of Lisdexamfetamine.
SulpirideSulpiride may decrease the stimulatory activities of Lisdexamfetamine.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Lisdexamfetamine.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Lisdexamfetamine.
ThioridazineThioridazine may decrease the stimulatory activities of Lisdexamfetamine.
ThiothixeneThiothixene may decrease the stimulatory activities of Lisdexamfetamine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Lisdexamfetamine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.
Vitamin CThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Lisdexamfetamine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Lisdexamfetamine.
Food InteractionsNot Available

Targets

1. Alpha-1B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Sodium-dependent dopamine transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent dopamine transporter Q01959 Details

References:

  1. Hamidovic A, Dlugos A, Palmer AA, de Wit H: Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010 Mar;40(2):255-61. Epub 2010 Jan 21. Pubmed

Comments
comments powered by Disqus
Drug created on May 14, 2007 19:24 / Updated on September 16, 2013 17:13